This article is more than 5 years old. Information may no longer be current.
Aptar, Kali Care join to address adherence in clinical trials
Click Here to Manage Email Alerts
Aptar Pharma, a leader in drug delivery systems, has partnered with Kali Care, a Silicon Valley-based technology company, to create solutions for adherence in ophthalmic clinical trials.
In an effort to reduce cost and complexity in trials, Aptar announced in a press release that it will combine its device expertise with Kali Care’s digital monitoring systems, which have senor technology that collect real-time data on adherence.
Clinical trials that use eye drops as a delivery system have challenges, which Aptar and Kali Care hope to solve by combining technologies. Aptar said an added benefit will be more accurate and timely data collection.
Salim Haffar, president of Aptar Pharma, and Sina Fateh, MD, founder and CEO of Kali Care, said in a joint statement: “Clinicians are now able to rely on objective and accurate data. Aptar Pharma’s leading dispensing technologies combined with Kali Care’s smart sensors, data analytics and cloud services will help make clinical trials more efficient and effective. This allows [clinicians] to improve risk strategies to distinguish patients requiring minimal support from those who require closer monitoring.”